USAResearch and clinical trials
Intravenous trehalose did not slow ALS in a phase 2/3 study
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Trehalose was tested in the HEALEY ALS study, carried out at 60 centers in the USA. 120 people received trehalose and 205 received placebo. Treatment lasted 24 weeks. Trehalose did not significantly slow the rate of disease progression compared with placebo. Serious side effects were more common in the trehalose group.
What does it mean for patients and families?
This result is negative, and no benefit of trehalose in ALS could be shown. Negative results also help researchers move in the right direction.
Source
Scientific paper: Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology, 2025. DOI: 10.1016/S1474-4422(25)00173-5 · PubMed 40409314
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Amyotrophic lateral sclerosis (ALS)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.